Study of the Effect of Sildenafil on Improving Chronic Lung Disease of neonates

evaluation of the therapeutic effect of sildenafil in neonates with chronic lung disease Comparison of oxygen demand in sildenafil patients and controls Comparison of hospital stay, pulmonary pressure and Systemic Blood Pressure Changes in sildenafil patients and controls

randomized clinical trial with parallel Controlled group, single-blind

Approximately 40 patients (those referred to Al-Zahra Hospital with a diagnosis of chronic lung disease in one year) will enter the study in accordance with the entry and exit criteria. Patients will be divided into control and study groups using Randomiser.org. All patients will receive routine and necessary measures, and after obtaining written consent from the parents to participate in the study, and confirmation of increased pulmonary pressure by echocardiography performed by a pediatric cardiologist, sildenafil tablets in the intervention group and placebo It will start as a form of control in the control group for patients, and parents will not know about the drug or placebo.

Inclusion criteria : Chronic lung disease based on the need for oxygen at 36 weeks of gestation Neonatal hemodynamic stability Lack of gastrointestinal disorders Written consent of the patient's parents to participate in the study  Output Criteria: Need oxygen at 36 weeks of intrauterine age for known causes other than -Nutritional intolerance

Intervention group: Sildenafil 50 mg tablets of Obaidi company with a dose of 2 mg per kilogram of body weight will be given to infants orally every 8 hours. Control group: The placebo will start as a single form and one color with the same characteristics of sildenafil tablets for patients.

Arterial oxygen saturation control Reduction of hospital stay Systemic blood pressure control Pulmonary blood pressure control

Using Random allocation software: Random allocation software. So that all patients who were hospitalized in Al-Zahra Medical Center in Tabriz in 1398 and 1399 with the diagnosis of chronic lung disease and had entry criteria and no exit criteria, will enter the study. Using the software, they will be divided into two groups.

All patients will undergo routine measures such as respiratory support and oxygen therapy, and after obtaining written consent from parents to participate in the study, sildenafil 50 mg overdose tablets at a dose of 2 mg per Kg of body weight will be started every 8 hours in the intervention and placebo tablets in the same color form as patients with the same characteristics in the control group.